Effect size of controlled trials comparing DMARDs or NSAIDs with placebo or other DMARDs in patients with PsA
| Drug | First author | Ntt/Ncomp | Mean dose | Comparator | SJC (*TJC) (**active JC) | Pain(*patient global assessment) | HAQ | Skin | ESR (*CRP) | Physician global assessment |
|---|---|---|---|---|---|---|---|---|---|---|
| MTX | Scarpa 12 | 16/19 | 10 mg/w IM | NSAID | +0.33(−0.34 to 1) | −0.15 (−0.81 to 0.52) | −0.30(−0.97 to 0.37) | 0.00(−0.67 to 0.67) | ||
| Black11 | 10/11 | 1–3 mg/kg/d3 inj/10 j | Placebo | +++ | ++ | |||||
| Willkens13 | 16/21 | 10 mg/w po | Placebo | +++ | ++ | ++ | +++ | |||
| Spadaro39 | 18/17 | 7.5–15 mg/w po | CSA 3–5 mg/kg/d | 0.14(−0.53 to 0.80) | *−0.02(−0.68 to 0.65) | PASI−0.41(−1.08 to 0.26) | 0.16(−0.50 to 0.83) | ++0.59(−0.08 to 1.27) | ||
| SSZ | Salvarani27 | 32/31 | 300 mg–3 g/d | Tt symptom. | +0.42(−0.08 to 0.92) | +0.29(−0.20 to 0.79) | PASI0.35(−0.15 to 0.85) | ++0.55(0.05 to 1.05) | ||
| Dougados23 | 179/172 | 500 mg–3 g/d | Placebo | +0.47(0.03 to 0.90) | +0.37(0.16 to 0.58) | +0.31(0.10 to 0.52) | ||||
| Clegg21 | 109/112 | 500 mg–2 g/d | Placebo | 0.02(−0.24 to 0.28) | % surface0.14(−0.12 to 0.40) | +0.40(0.14 to 0.67) | ||||
| Fraser25 | 19/20 | 500 mg–40 mg/kg/d | Placebo | +++ | + | |||||
| Farr24 | 15/15 | 500 mg–2 g/d | Placebo | – – | 0 | |||||
| Combe22 | 53/64 | 500 mg–2 g/d | Placebo | *0.17(−0.19 to 0.53) | +0.46(0.09 to 0.83) | +0.28(−0.09 to 0.65) | ||||
| Gupta26 | 10/14 | 1.5 g–3 g/d | Placebo | 0.07(−0.74 to 0.89) | ++0.64(−0.19 to 1.48) | +++1.39(0.49 to 2.29) | ||||
| Salvarani27 | 32/36 | 300 mg–3 g/d | CSA 3–5 mg/kg/d | 0.00(−0.48 to 0.48) | - - -−0.98(−1.49 to −0.48) | +PASI0.26(−0.22 to 0.73) | - -−0.52(−1.0 to −0.03) | |||
| CSA | Fraser30 | 38/34 | 2.5–4 mg/kg/d | Placebo | 0.13(−0.33 to 0.59) | +0.26(−0.20 to 0.73) | −0.18(−0.64 to 0.28) | +PASI0.36(−0.11 to 0.82) | −0.12(−0.58 to 0.34) | |
| Salvarani27 | 36/31 | 3–5 mg/kg/d | Tt symptom. | +0.45(−0.04 to 0.94) | +++1.25(0.72 to 1.77) | PASI0.16(−0.32 to 0.64) | +++1.14(0.62 to 1.66) | |||
| LEF | Kaltwasser32 | 95/91 | 20 mg/d | Placebo | 0.14(−0.14 to 0.43) | +0.24(−0.05 to 0.53) | +PASI0.20(−0.09 to 0.50) | +*0.30(0.00 to 0.59) | ||
| AUR | Carette35 | 120/118 | 3–4.5 mg/d | Placebo | 0.05(−0.23 to 0.34) | +0.40(0.11 to 0.69) | +*0.43(0.15 to 0.72) | % surface0.11(−0.18 to 0.39) | ||
| Palit36 | 29/26 | 3 mg/d | Placebo | – – – | + | |||||
| GoldIM | Palit36 | 27/26 | 50 mg | Placebo | 0 | ++ | ||||
| Palit36 | 27/29 | 50 mg | Auranofin 3 mg/d | +++ | + | |||||
| Brückle37 | 21/21 | 50 mg/w | Auranofin6 mg/d | + | ||||||
| AZA | Levy67 | 3/3 | 3 mg/kg | Placebo | +++**0.92(−0.76 to 2.60) | |||||
| Fumaric acid | Peeters68 | 13/14 | 120 –720 mg | Placebo | 0.00(−0.75 to 0.75) | ++0.56(−0.20 to 1.33) | +++% surface0.99(0.19 to 1.79) | ++0.78(0.00 to 1.57) | ||
| Nimesulide | Sarzi-Puttini6 | 20/20 | 200 mg | Placebo | ++0.61(−0.03 to 1.24) | ++0.70(0.06 to 1.34) | ||||
| Sarzi-Puttini6 | 20/20 | 400 mg | Placebo | ++0.75(0.11 to 1.39) | +0.36(−0.26 to 0.99) |
The magnitude of the effect size is represented by + (small effect size, 0.2–0.5), ++ (moderate effect size, 0.5–0.8) or +++ (large effect size, ≥0.8). Where calculations were possible, results are presented as effect (95% CI). For indicative results, when SD was estimated from other trials, the effect size is shown only as +, ++ or +++.
- -, −−− Negative effect sizes
Significant results are in bold type.
AUR, auranofin; AZA, azathioprine; CRP, C reactive protein; CSA, cyclosporin A; D, day; DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; IM, intramuscular; JC, joint count; LEF, leflunomide; MTX, methotrexate; Ntt/Ncomp, number of patients on treatment/number of patients on comparator; NSAID, non-steroidal anti-inflammatory drug; PASI, psoriasis area and severity index; po, orally; PsA, psoriatic arthritis; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count; w, week.